Literature DB >> 27177407

Recurrent episodes of anaphylaxis in a patient with haemophilia B: a case report.

Margherita Mauro1, Elisa Bonetti1, Rita Balter1, Giovanni Poli2, Simone Cesaro1.   

Abstract

Entities:  

Year:  2016        PMID： 27177407      PMCID： PMC5111390          DOI： 10.2450/2016.0297-15

Source DB:  PubMed          Journal:  Blood Transfus        ISSN： 1723-2007            Impact factor:   3.443


× No keyword cloud information.
  16 in total

1.  Anaphylactic response to factor IX replacement therapy in haemophilia B patients: complete gene deletions confer the highest risk.

Authors:  E C Thorland; J B Drost; J M Lusher; I Warrier; A Shapiro; M A Koerper; D Dimichele; J Westman; N S Key; S S Sommer
Journal:  Haemophilia       Date:  1999-03       Impact factor: 4.287

Review 2.  Anaphylaxis in patients with congenital bleeding disorders and inhibitors.

Authors:  Massimo Franchini; Giuseppe Lippi; Martina Montagnana; Giovanni Targher; Marco Zaffanello; Gian Luca Salvagno; Gianna Franca Rivolta; Caterina Di Perna; Annarita Tagliaferri
Journal:  Blood Coagul Fibrinolysis       Date:  2009-06       Impact factor: 1.276

3.  Successful eradication of inhibitor in a patient with severe haemophilia B and anaphylaxis to factor IX concentrates: is there a role for Rituximab and desensitization therapy?

Authors:  S Gamerman; A M Singh; M Makhija; A Sharathkumar
Journal:  Haemophilia       Date:  2013-08-28       Impact factor: 4.287

Review 4.  Factor IX: molecular structure, epitopes, and mutations associated with inhibitor formation.

Authors:  K A High
Journal:  Adv Exp Med Biol       Date:  1995       Impact factor: 2.622

5.  Measurement of anti-factor IX IgG subclasses in haemophilia B patients who developed inhibitors with episodes of allergic reactions to factor IX concentrates.

Authors:  Y Sawamoto; M Shima; M Yamamoto; S Kamisue; H Nakai; I Tanaka; K Hayashi; J C Giddings; A Yoshioka
Journal:  Thromb Res       Date:  1996-08-15       Impact factor: 3.944

6.  Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (1997-2006).

Authors:  M Chitlur; I Warrier; M Rajpurkar; J M Lusher
Journal:  Haemophilia       Date:  2009-06-10       Impact factor: 4.287

7.  Inhibitors in haemophilia B: the Italian experience.

Authors:  G Castaman; E Bonetti; M Messina; M Morfini; A Rocino; F A Scaraggi; G Tagariello
Journal:  Haemophilia       Date:  2013-04-22       Impact factor: 4.287

8.  The North American Immune Tolerance Registry: contributions to the thirty-year experience with immune tolerance therapy.

Authors:  D Dimichele
Journal:  Haemophilia       Date:  2008-10-30       Impact factor: 4.287

9.  Development of anaphylactic shock in haemophilia B patients with inhibitors.

Authors:  I Warrier; J M Lusher
Journal:  Blood Coagul Fibrinolysis       Date:  1998-03       Impact factor: 1.276

Review 10.  Desensitization and immune tolerance induction in children with severe factor IX deficiency; inhibitors and adverse reactions to replacement therapy: a case-report and literature review.

Authors:  Andrea Bon; Massimo Morfini; Alessandro Dini; Francesca Mori; Simona Barni; Sottilotta Gianluca; Maurizio de Martino; Elio Novembre
Journal:  Ital J Pediatr       Date:  2015-02-19       Impact factor: 2.638
View more
  3 in total

1.  Nonacog beta pegol (N9-GP) in hemophilia B: First report on safety and efficacy in previously untreated and minimally treated patients.

Authors:  Anthony K Chan; Jayanthi Alamelu; Chris Barnes; Ampaiwan Chuansumrit; May-Lill Garly; Rikke Medom Meldgaard; Guy Young
Journal:  Res Pract Thromb Haemost       Date:  2020-07-29

2.  Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran-Results of the phase 1 inhibitor cohort.

Authors:  K John Pasi; Toshko Lissitchkov; Vasily Mamonov; Tim Mant; Margarita Timofeeva; Catherine Bagot; Pratima Chowdary; Pencho Georgiev; Liana Gercheva-Kyuchukova; Kate Madigan; Huy Van Nguyen; Qifeng Yu; Baisong Mei; Craig C Benson; Margaret V Ragni
Journal:  J Thromb Haemost       Date:  2021-05-18       Impact factor: 5.824

Review 3.  Albumin-Fusion Recombinant FIX in the Management of People with Hemophilia B: An Evidence-Based Review.

Authors:  Samantha Pasca; Ezio Zanon
Journal:  Drug Des Devel Ther       Date:  2022-09-15       Impact factor: 4.319
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.